Literature DB >> 22992948

Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression.

Ling Yu1, Shiqing Liu, Weichun Guo, Bo Zhang, Yi Liang, Qisheng Feng.   

Abstract

It has been reported that overexpression of Mad2 in transgenic mice leads to a wide variety of tumors, and Mad2 overexpression causes lung tumor relapse after oncogene withdrawal. In a previous study we demonstrated that Mad2 is abnormally upregulated in human osteosarcoma, however, the underlying mechanisms remain unknown. In this study, we found that transient Mad2 overexpression is sufficient to cause early dyscrasia and decreased survival in a xenotransplantation osteosarcoma mouse model, and Mad2 overexpression is associated with increased invasiveness and pulmonary metastasis. We also found that upregulation of Mad2 was accompanied by enhanced capability to self-renew. Our data validate the correlation between upregulation of Mad2 and osteosarcoma advancement, and that the underlying mechanisms involve the increase of invasiveness and cancer stem cell properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22992948     DOI: 10.3892/or.2012.2032

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  A role of WT1 in cell division and genomic stability.

Authors:  Jayasha Shandilya; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma.

Authors:  Po Eun Park; Ji Yun Jeong; Sun Zoo Kim; Ji Young Park
Journal:  Korean J Pathol       Date:  2013-10-25

3.  Structure-biological function relationship extended to mitotic arrest-deficient 2-like protein Mad2 native and mutants-new opportunity for genetic disorder control.

Authors:  Speranta Avram; Adina Milac; Maria Mernea; Dan Mihailescu; Mihai V Putz; Catalin Buiu
Journal:  Int J Mol Sci       Date:  2014-11-18       Impact factor: 5.923

4.  Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.

Authors:  Ana Vanessa Nascimento; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Mol Pharm       Date:  2014-09-26       Impact factor: 4.939

5.  Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel.

Authors:  Tonghai Huang; Lin Yang; Guangsuo Wang; Guanggui Ding; Bin Peng; Yuxin Wen; Zheng Wang
Journal:  Onco Targets Ther       Date:  2017-01-18       Impact factor: 4.147

6.  The association between MAD2 and prognosis in cancer: a systematic review and meta-analyses.

Authors:  Tara Byrne; Helen G Coleman; Janine A Cooper; W Glenn McCluggage; Amanda McCann; Fiona Furlong
Journal:  Oncotarget       Date:  2017-06-08

7.  Exploring the molecular mechanisms of osteosarcoma by the integrated analysis of mRNAs and miRNA microarrays.

Authors:  Hao Shen; Wei Wang; Bingbing Ni; Qiang Zou; Hua Lu; Zhanchao Wang
Journal:  Int J Mol Med       Date:  2018-03-27       Impact factor: 4.101

Review 8.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.